Table of Contents

company-logo

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Outlook Therapeutics Dividend Announcement

• Outlook Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Outlook Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Outlook Therapeutics Dividend History

Outlook Therapeutics Dividend Yield

Outlook Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Outlook Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Outlook Therapeutics Financial Ratios

P/E ratio-1.26
PEG ratio0.00
P/B ratio-1.42
ROE146.56%
Payout ratio0.00%
Current ratio1.07
Quick ratio1.07
Cash Ratio0.75

Outlook Therapeutics Dividend FAQ

Does Outlook Therapeutics stock pay dividends?
Outlook Therapeutics does not currently pay dividends to its shareholders.
Has Outlook Therapeutics ever paid a dividend?
No, Outlook Therapeutics has no a history of paying dividends to its shareholders. Outlook Therapeutics is not known for its dividend payments.
Why doesn't Outlook Therapeutics pay dividends?
There are several potential reasons why Outlook Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Outlook Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Outlook Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Outlook Therapeutics a dividend aristocrat?
Outlook Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Outlook Therapeutics a dividend king?
Outlook Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Outlook Therapeutics a dividend stock?
No, Outlook Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Outlook Therapeutics stocks?
To buy Outlook Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Outlook Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.